Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acetaminophen

This article was originally published in The Tan Sheet

Executive Summary

Questions of whether analgesic depletes glutathione and should carry label warning against excessive use by HIV-infected individuals "are being addressed" in FDA's evaluation of acetaminophen toxicity "in various populations, in specific clinical situations and at different dosages," agency says. In an interim response to a petition from Leonore Herzenberg, PhD, Stanford University, requesting such a warning, FDA notes its analysis "includes a review of the possible need for revised labeling." FDA is examining more extensive ways to inform consumers of acetaminophen risks and limit OTC access. Agency also is reviewing McNeil's request to expand age groups for OTC pediatric dosing instructions
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS092970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel